Raffaele Colombo: Dato-DXd approved in Japan for HR+, HER-negative unresectable or recurrent breast cancer

Raffaele Colombo: Dato-DXd approved in Japan for HR+, HER-negative unresectable or recurrent breast cancer

Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared on X:

“Datopotamab deruxtecan (dato-DXd) approved in Japan for the treatment of patients with hormone receptor positive (HR+), HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.

Brand name: DATROWAY

Approval based on TROPION-Breast01 study.”

Raffaele Colombo: Dato-DXd approved in Japan for HR+, HER-negative unresectable or recurrent breast cancer

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Authors: Aditya Bardia et al.

Raffaele colombo

Raffaele Colombo is the Associate Director of Medicinal Chemistry at Zymeworks. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.

Aditya Bardia Barbara Pistilli Binghe Xu cancer David W. Cescon Erika Hamilton Giuliano Borges Hope S. Rugo Junji Tsurutani Kevin Kalinsky Komal Jhaveri Lu Xu Masaya Hattori Michelino De Laurentiis Neelima Denduluri Noelia Martínez Jañez OncoDaily Oncology Pedro Emanuel Rubini Liedke Qingyuan Zhang Raffaele Colombo Rick M. Fairhurst Sabrina Khan Seock-Ah Im Shusen Wang Sonia Pernas. Yen-Shen Lu